Latest News

Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03.NOTTINGHAM, UK; November 29, 2022 – Quotient Sciences, a global drug d...

Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, announced that it has commenced the first human subject dosing with OXL001. The study is being conduced with Quotient Scien...

Emplicure AB reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain. The program is supported by Quotient Sciences Translational Pharmaceutics® platform.Emplicure today ...

A £6 million project expands Quotient Sciences' Alnwick, UK into a state-of-the-art drug substance manufacturing facility that can deliver integrated support for customers from candidate selection through to early clinical development ...

Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, and Quotient Sciences, a drug development and manufacturing accelerator, today announced an update on the development of Ox...